Abstract
In a little over two decades, the treatment of rheumatoid arthritis (RA) has changed dramatically. Nine different biologicals, with five different modes of action, and a new class of targeted synthetic medications have been approved and are being used in the care of millions of patients, and long-term outcomes have improved considerably. What factors have contributed to this unprecedented success, and can similar results be obtained in the treatment of systemic lupus erythematosus (SLE)?
The following key ingredients of the RA success story will be discussed.
Clinical and structural outcomes for RA were intensively studied and accurately defined before the key clinical trials were launched.
Industry-sponsored and investigator-initiated clinical trials, often running in parallel, delivered complementary knowledge and insights.
Once approved, rheumatologists and their patients embraced the new developments, testing the possibilities and gathering data in registries, rapidly acquiring extensive practical experience.
I will discuss how similar approaches can be implemented in the development of new therapies for SLE. Although progress in this disease has been slow in coming, I will argue that the main conditions have now been fulfilled to accomplish significant beneficial changes in lupus therapeutics in the coming years.
Learning Objectives
Describe why defining clinical and structural outcomes in RA was important to assessing benefit of novel treatments
Discuss advances in RA treatment and how drivers of successful treatment can be applied to treating SLE
Explain how practical experiences with novel treatments in RA have benefited patients and how similar experiences may benefit patients with SLE
